In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of $63.00. The company’s ...

The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular med Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings.

TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research Report). The company’s shares closed yesterday at $12.94.